Why TRT Raised Your Blood Pressure (and How to Fix It)

Your cardiovascular system is a pressure system, and like any pressure system, it responds to three things: the viscosity of the fluid moving through it, the volume of that fluid, and the strength of the pump pushing it. Testosterone therapy touches all three, and when any one of them goes unmanaged, your blood pressure reflects that.

That is the map. Now walk through each part.

The first and most significant driver is something called erythrocytosis, which is when testosterone stimulates your bone marrow to produce more red blood cells than your vessels were designed to carry at once. Testosterone signals the kidneys to release erythropoietin, a hormone that tells bone marrow to ramp up red blood cell output, and the effect scales with your dose in a direct, linear way. The more testosterone you take, the more red blood cells you make. That has been confirmed in dose-escalation studies going back to 2008.

Think of your blood like a river carrying both water and sediment. When the sediment load increases, the river gets thicker, flows more slowly, and pushes harder against its banks. That pressure is what your heart is working against every beat.

A randomized controlled trial published in the Journal of Hypertension measured this directly. Men whose hematocrit, which is the percentage of your blood that is red blood cells, rose by more than 6% on testosterone saw their systolic blood pressure climb 13.2 mmHg compared to placebo. That is not a small number. For context, most first-line blood pressure medications lower systolic by roughly 10 mmHg. A hematocrit shift alone can erase that gain entirely.

The threshold that triggers clinical concern is 54%. Above that, the current guidance in the European Urology literature recommends dose reduction or discontinuation. Not a blood donation by default, not waiting to see what happens. A protocol change first. Because the goal of managing hematocrit is to address the source, which is the stimulus driving red blood cell production, not just the output.

The second driver is estradiol, and this is where a lot of men on TRT end up worse off than they started because of how clinics respond to the problem.

Your body converts testosterone into estradiol through a process called aromatization, which is a normal enzymatic reaction that happens primarily in fat tissue and the liver. When testosterone levels rise sharply, more of it converts to estradiol, and estradiol at elevated levels causes your kidneys to retain sodium and water through direct effects on the renal tubules. More fluid volume means more pressure in the system.

That part most people understand. What fewer people understand is what happens when you try to block aromatization too aggressively.

Aromatase inhibitors, drugs designed to block the conversion of testosterone to estradiol, will bring estradiol down. But estradiol is not simply a side effect to be suppressed. It plays an active protective role in cardiovascular function, including maintaining blood vessel flexibility and supporting healthy blood pressure regulation. Research in animal models has shown that blocking aromatase raises mean arterial pressure and produces markers of kidney injury. The cardiovascular system needs estradiol operating in a functional range, not crushed.

So the men who get on TRT, develop high estradiol, get prescribed an aromatase inhibitor, and then push their estradiol below 20 picograms per milliliter end up with blood pressure problems coming from the opposite direction. You traded one imbalance for another.

The practical fix is not pharmaceutical. Injection frequency determines how large your testosterone peaks are between doses, and larger peaks produce larger estradiol spikes. Moving from a single weekly injection to smaller doses two or three times per week smooths the curve and reduces the peak conversion load. A sensitive estradiol test, not the standard immunoassay but the LC-MS/MS method designed for men, should put you somewhere between 20 and 40 picograms per milliliter. That range appears to be where cardiovascular function is supported without the water retention effects of excess.

The third driver is the one that does not show up in your labs at all.

Testosterone increases blood volume through its effects on fluid retention and red blood cell mass, and your cardiovascular system needs time and conditioning to adapt to that expanded volume. The adaptation mechanism is your heart becoming a more efficient pump and your blood vessels becoming more responsive, and that adaptation is driven by aerobic exercise.

Without cardio, the expanded volume sits in a system that has not grown its capacity to handle it. The result is higher resting pressure because the pump is not strong enough and the vessels are not responsive enough to distribute the load efficiently. This is not a theoretical concern. It is the same reason athletes who train aerobically have lower resting blood pressure than sedentary people at the same body weight.

When all three of these variables are actually managed, the picture changes completely. A study following 737 men on long-term testosterone therapy found that among those not already on antihypertensives, systolic blood pressure dropped by approximately 12.5 mmHg over the course of treatment. In a separate cohort of 202 men on testosterone, 33 who had been taking blood pressure medication were able to discontinue it entirely.

That is the same hormone, producing the opposite cardiovascular outcome, because the protocol was managed instead of ignored.

Hematocrit checked every six months, with a hard look at dose if it exceeds 54%. Estradiol measured with the right test and managed through injection frequency before any pharmaceutical is added. And aerobic exercise treated as part of the protocol, not optional. Those are the three levers.

TRT does not have a blood pressure problem. Unmonitored TRT does.

---

References

1. Olesen TB, Glintborg D, Johnk F, et al. 2024. Blood pressure responses to testosterone therapy are amplified by hematocrit levels in opioid-induced androgen deficiency. Journal of Hypertension, 423, 531-540. Finding: Office SBP increased 6.2 mmHg in testosterone group vs 7.0 mmHg decrease in placebo net 13.2 mmHg. Men with hematocrit rise >6% saw clinically relevant BP increases. Source
2. Coviello AD, Kaplan B, Lakshman KM, et al. 2008. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. Journal of Clinical Endocrinology and Metabolism, 933, 914-919. Finding: Hemoglobin and hematocrit increased in a linear, dose-dependent fashion. Source
3. Almutlaq RN, Newell-Fugate AE, Evans LC, et al. 2022. Aromatase inhibition increases blood pressure and markers of renal injury in female rats. American Journal of Physiology Renal Physiology, 3232, F170-F181. Finding: Blocking aromatase increased mean arterial pressure. Source
4. Hackett G, Mann A, Haider A, et al. 2024. Testosterone replacement therapy: effects on blood pressure in hypogonadal men. World Journal of Mens Health, 422, 431-443. Finding: Long-term TRT associated with significant SBP and DBP reductions. 33 of 202 men on antihypertensives discontinued them. Source
5. Agrawal P, Singh SM, Kohn T. 2023. Management of erythrocytosis in men receiving testosterone therapy. European Urology Focus, 91, 139-142. Finding: Hematocrit >54% requires dose decrease or discontinuation. Source
6. Johannsson G, Gibney J, Wolthers T, et al. 2005. Independent and combined effects of testosterone and growth hormone on extracellular water in hypopituitary men. Journal of Clinical Endocrinology and Metabolism, 907, 3891-3896. Finding: Testosterone independently increased extracellular water through renal tubule effects. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness